Scarica l'app Stockscreener
3.85
6.33%
-0.26
Galmed Pharmaceuticals Ltd Borsa (GLMD) Ultime notizie
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated by Analysts at StockNews.com - Defense World
How does GLMD’s price to cash per share ratio compare in the market? - US Post News
GLMD: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Financial Analysis: Galmed Pharmaceuticals Ltd (GLMD)’s Ratios Unveil Key Insights - The Dwinnex
Galmed Pharmaceuticals Secures $10M Equity Agreement - TipRanks
Investing in Galmed Pharmaceuticals Ltd (GLMD) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Galmed Phar stock hits 52-week low at $0.26 amid challenges - Investing.com
Galmed Phar stock hits 52-week low at $0.26 amid challenges - Investing.com Canada
Galmed Pharmaceuticals Reports Mid-Year Loss - TipRanks
Galmed Pharmaceuticals Announces Reverse Stock Split - TipRanks
Ratios Reveal: Breaking Down Galmed Pharmaceuticals Ltd (GLMD)’s Financial Health - The Dwinnex
Galmed Pharmaceuticals Ltd (GLMD) Stock: A Year of Stock Market Dynamics - The InvestChronicle
The time has not yet come to remove your chips from the table: Galmed Pharmaceuticals Ltd (GLMD) - SETE News
Galmed Pharmaceuticals Ltd (GLMD) Stock: A Year of Highs and Lows - The InvestChronicle
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Crosses Below 200-Day Moving Average of $0.35 - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com - Defense World
Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World
Liver Fibrosis Drugs Market Size 2032 | Inventiva Pharma, Galmed - openPR
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 1,185.7% in July - Defense World
Nash Market Report | Novo Nordisk, Galmed Pharmaceuticals, Genfit Intercept - Economica
Galmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews.com - Defense World
Galmed Shareholders Approve Key Resolutions - TipRanks
Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World
Galmed Pharmaceuticals Reschedules AGM - TipRanks
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving PremarketMainz Biomed ... - Benzinga
Non-Alcoholic Steatohepatitis (NASH) Treatment Market Business Insights, Key Trend Analysis | Allergan Plc (Tobira ... - Economica
Galmed Pharmaceuticals (NASDAQ:GLMD) Earns Sell Rating from Analysts at StockNews.com - Defense World
Is Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) CEO Overpaid Relative To Its Peers? - Yahoo Lifestyle UK
Galmed Pharmaceuticals (NASDAQ:GLMD) Research Coverage Started at StockNews.com - Defense World
StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
How Is Galmed Pharmaceuticals' (NASDAQ:GLMD) CEO Paid Relative To Peers? - Yahoo Sport Australia
Galmed Pharmaceuticals Calls for Shareholder VotesTipRanks.com - TipRanks
Nash Market 2024 [SWOT] Analysis | Novo Nordisk, Galmed Pharmaceuticals, Genfit Intercept - Weekly Post Gazette
StockNews.com Initiates Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World
Galmed Pharma Reports Q1 2024 FinancialsTipRanks.com - TipRanks
Galmed Pharmaceuticals Ltd expected to post a shareEarnings Preview - XM
Market Watch: Galmed Pharmaceuticals Ltd (GLMD)'s Noteworthy Drop, Closing at 0.39 – DWinneX - The Dwinnex
Are Institutions Heavily Invested In Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) Shares? - Yahoo New Zealand News
How Galmed (GLMD) Stock Stands Out in a Strong Industry - Yahoo Lifestyle UK
Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Passes Below 200 Day Moving Average of $0.38 - Defense World
How Galmed (GLMD) Stock Stands Out in a Strong Industry - Yahoo Singapore News
Are Institutions Heavily Invested In Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) Shares? - Yahoo Lifestyle UK
Galmed Pharmaceuticals Provides Business Update and Reports Third Quarter 2019 Financial Results - PR Newswire
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024 - InvestorPlace
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Markets Insider
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 - PR Newswire
Galmed Pharmaceuticals Granted Nasdaq ExtensionTipRanks.com - TipRanks
Galmed Pharmaceuticals Granted Nasdaq Extension - TipRanks
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? - The Motley Fool
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis - BioSpace
Israeli med-tech cos among best and worst Nasdaq stocks - Globes
Why American Eagle Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Tuesday's Mid-Day ... - Markets Insider
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study - PR Newswire
Non-Alcoholic Steatohepatitis (NASH) Market to Hit $21.47 Billions by 2025 | Current Trends and Industry Analysis - PharmiWeb.com
Financial Adviser Sues Pharma Biz Over Merger Fees - Law360
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification - PR Newswire
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering - PR Newswire
1.19%
1.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):